Dr. Reddy’s reduces price of trusted cardiovascular drug Cidmus

365Telugu.com Onaline news,Hyderabad, January 21, 2023 :Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”) announced a significant price reduction of its trusted cardiovascular drug Cidmus.

It is a pharmaceutical composition containing a combination of
sacubitril and valsartan, indicated for heart failure patients with reduced ejection fraction.

Dr. Reddy’s Cidmus® tablets are available in three strengths – 50mg, 100mg and 200mg, to be taken twice a
day. Following the price reduction, Cidmus® will be priced at Rs. 29 for 50mg (down from Rs. 78.32), Rs. 49 for
100mg (down from Rs. 83.86) and Rs. 79 for 200mg (down from Rs. 96.71) per tablet. The product will be
manufactured in-house.

The Active Pharmaceutical Ingredient (API) of Cidmus® is manufactured at a USFDA-
approved facility. Dr. Reddy’s Cidmus® has a co-crystal formulation that enhances bioavailability, solubility and
physical and chemical properties of the drug 1 .
There is a growing incidence of chronic diseases in India, and heart failure is one of them. It is estimated that
India has between 8-10 million heart failure patients 2 .

Dr. Reddy’s acquired the cardiovascular brand Cidmus®
from Novartis AG in 2022 for the India market. Driven by the company’s strong marketing and distribution
network, Cidmus® has reached over 1 lakh patients in India with a market share of 32% 3 . Cidmus® is part of a
trusted portfolio of medicines offered to patients in the cardiovascular segment by Dr. Reddy’s alongside its
leading brands such as Stamlo®, Stamlo® Beta, Reclide®-XR and Reclimet®-XR. This price reduction will
further widen access to this trusted and established brand in keeping with its purpose of ‘Good Health Can’t